166 related articles for article (PubMed ID: 35216305)
1. Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus Leiomyosarcoma.
Machado-Lopez A; Alonso R; Lago V; Jimenez-Almazan J; Garcia M; Monleon J; Lopez S; Barcelo F; Torroba A; Ortiz S; Domingo S; Simon C; Mas A
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216305
[TBL] [Abstract][Full Text] [Related]
2. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
4. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
5. Identification of uterine leiomyoma-specific marker genes based on DNA methylation and their clinical application.
Sato S; Maekawa R; Yamagata Y; Tamura I; Lee L; Okada M; Jozaki K; Asada H; Tamura H; Sugino N
Sci Rep; 2016 Aug; 6():30652. PubMed ID: 27498619
[TBL] [Abstract][Full Text] [Related]
6. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
7. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
8. A differential diagnosis between uterine leiomyoma and leiomyosarcoma using transcriptome analysis.
Kim K; Kim S; Ahn T; Kim H; Shin SJ; Choi CH; Park S; Kim YB; No JH; Suh DH
BMC Cancer; 2023 Dec; 23(1):1215. PubMed ID: 38066476
[TBL] [Abstract][Full Text] [Related]
9. Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas.
Mas A; Simón C
Biol Reprod; 2019 Dec; 101(6):1115-1123. PubMed ID: 30184111
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma.
Poncelet C; Walker F; Madelenat P; Bringuier AF; Scoazec JY; Feldmann G; Darai E
Hum Pathol; 2001 Nov; 32(11):1190-6. PubMed ID: 11727257
[TBL] [Abstract][Full Text] [Related]
11. Benign metastasizing leiomyoma of the lung: clinicopathologic, immunohistochemical, and micro-RNA analyses.
Nuovo GJ; Schmittgen TD
Diagn Mol Pathol; 2008 Sep; 17(3):145-50. PubMed ID: 18382364
[TBL] [Abstract][Full Text] [Related]
12. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
14. Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas.
Mittal KR; Chen F; Wei JJ; Rijhvani K; Kurvathi R; Streck D; Dermody J; Toruner GA
Mod Pathol; 2009 Oct; 22(10):1303-11. PubMed ID: 19633649
[TBL] [Abstract][Full Text] [Related]
15. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
16. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
Packenham JP; du Manoir S; Schrock E; Risinger JI; Dixon D; Denz DN; Evans JA; Berchuck A; Barrett JC; Devereux TR; Ried T
Mol Carcinog; 1997 Aug; 19(4):273-9. PubMed ID: 9290705
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
18. Different characteristics of mitochondrial microsatellite instability between uterine leiomyomas and leiomyosarcomas.
Lee JH; Ryu TY; Cho CH; Kim DK
Pathol Oncol Res; 2011 Jun; 17(2):201-5. PubMed ID: 20853077
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
20. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
